The use of CA IX inhibition with zonisamide (or acetazolamide) would be a realization of Koltai’s “repurposed drug combinations targeting this vulnerable side (i.e., decreased extracellular pH and need to export increased intracellular protons) of cancer development” [56]. The gene discussed is CA9; the disease is cancer.